OTC Watch

All stocks / RGBP

Regen BioPharma Inc RGBP

Regen BioPharma (RGBP): shares outstanding up 5209% in a year, convertible notes mentioned in an 8-K in November 2026, a late 10-Q notice in August 2026 and the latest annual figures in plain language. Each fact links to its SEC filing.

Costly financingLate filingDilutionEstimated float OTCIDCalifornia, USA
Live quote on OTC Markets

Market listing

Full name
REGEN BIOPHARMA INC
Market tier
OTC Pink Current
Trading status
Active
Last trade
09:35:00
Website
www.regenbiopharma.com
Source: Stockwatch, 2026-11-17

News headlines

Regen BioPharma, Inc. Provides Shareholder Update on Company's Activities and Direction
2026-11-05 09:30 ยท News Release
Headlines only, with links to the full item. Company press releases are written by the company.

The financial report, and what it means

Annual figures to 2025-09-30
The report says
Revenue
$236,561
Net loss
($1,274,502)
What it means

It spends more than it earns

Under strain

Customers paid it $236,561 in the year. It lost $1.3 million. For every $1 that came in, about $6.39 went out.

The report says
Cash and cash equivalents
$69,555
Net cash used in operating activities
($383,591)
What it means

The cash could run out soon

Under strain

It had $69,555 in the bank and used about $31,966 a month. At that pace the money lasts about 2 months unless it borrows or sells more shares.

The report says
Total assets
$274,628
Total liabilities
$6,555,811
What it means

It owes more than it owns

Under strain

Everything the company owns adds up to $274,628. Its debts and unpaid bills add up to $6.6 million. That is about $23.87 owed for every $1 owned.

What this adds up to

3 of 3 checks show strain. It spends more than it earns. The cash could run out soon. It owes more than it owns. These are facts from the company's own reports, not a recommendation.

Signals

Costly financing2026-11-02

8-K filed 2026-11-02 mentions: convertible note, equity line.

Rule: 8-K in the last 12 months mentioning convertible notes or an equity line. Source record

Late filing2026-08-13

Filed NT 10-Q on 2026-08-13: notice that a periodic report is late.

Rule: Late-filing notice (Form NT 10-K or NT 10-Q) in the last 12 months. Source record

Dilution2026-08-12

Shares outstanding rose from 31,554,704 (2025-06-30) to 1,675,277,503 (2026-08-12), up 5209%.

Rule: Shares outstanding up 20% or more in 12 months. Source record

Estimated float2026-08-12

Estimated float about 1,675,277,503 shares as of 2026-08-12: 1,675,277,503 outstanding minus 0 held by 0 reporting insider(s).

Rule: Estimated: shares outstanding minus the latest holdings insiders reported on Forms 3/4/5. Holders of 5% or more (13D/13G) are not yet subtracted. Source record

Shares outstanding

Source: SEC filings
2025-09-30
39.4M
2025-12-26
108.1M
2025-12-31
108.1M
2026-02-02
129.5M
2026-03-31
351.4M
2026-05-01
512.0M
2026-06-30
1.13B
2026-08-12
1.68B

Price chart

Chart by TradingView. We do not store or publish prices. Live quote on OTC Markets

Recent filings

2026-11-02 8-K8-K
2026-08-17 10-Q10-Q
2026-08-13 NT 10-QNT 10-Q
2026-07-15 8-K8-K
2026-05-14 10-Q10-Q
2026-03-04 8-K8-K
2026-02-13 10-Q10-Q
2026-02-02 8-K8-K
2026-01-21 8-K8-K
2026-01-12 QUALIF
2026-01-08 1-A POS
2025-12-30 10-K10-K

Common questions about RGBP

Does RGBP file reports with the SEC?

Yes. Regen BioPharma files with the SEC under company number 0001589150. The most recent filing we hold is a 8-K dated 2026-11-02.

Source record

How many RGBP shares are outstanding?

1,675,277,503 shares as of 2026-08-12, as reported to the SEC. That is up 5209% from 31,554,704 on 2025-06-30.

Source record

Has RGBP filed reports late?

Yes. In the last 12 months it filed 1 late-filing notice, most recently a NT 10-Q on 2026-08-13. A notice means a report was not ready on time; check whether the report followed.

Source record

Is Regen BioPharma making money?

Customers paid it $236,561 in the year. It lost $1.3 million. For every $1 that came in, about $6.39 went out. (Annual figures to 2025-09-30. Facts from the company's own report, not a recommendation.)

Source record